Camlin Fine Sciences Limited · NSE:CAMLINFINE
Camlin Fine Sciences — Q3 FY19 Earnings Presentation
25 slides from Camlin Fine Sciences's earnings presentation, Feb 8, 2019
Slide 1: Stock exchange intimation letter for investor presentation
> Camlin Fine Sciences Date: 08/02/2019 To, BSE Limited, 25, P. J. Towers, Dalal Street, Mumbai — 400 001 Ref: Company Scrip Code: 532834 To, The Manager, Listing Department, National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 Ref: Symbol: CAMLI
Slide 2: Earnings Presentation 9M / Q3-FY19
EARNINGS PRESENTATION 9M / Q3-FY19
Slide 3: Executive Summary
2 Executive Summary 2 Company Overview Financials FY18 (INR Mn) • Camlin Fine Sciences Limited (CFS), formed in 2006 after demerging the fine chemical business from Camlin Ltd., is a vertically integrated company Revenue engaged in research, development, manufacturing, commercializing and marketing
Slide 4: Snapshot
3 SNAPSHOT One of the few Leading Manufacturers of vertically and Antioxidants in the world 3rd largest producer of backward with more than 25 years of Vanillin in the world integrated players experience Strategic move to start Serving more than 80 blends which have higher countries with over Prefer
Slide 5: About the Company
4 About the Company • In 2006, Camlin Fine Sciences Limited (CFS) was formed after de-merging (mirror Total Operational Revenue (INR Mn) shareholding) the fine chemical business from Camlin Ltd. 8,000 7,228 • The Company has over 30 years of experience providing innovative solutions with a 6,241 com
Slide 6: 9M / Q3-FY19 Financial Overview
5 9M / Q3-FY19 FINANCIAL OVERVIEW
Slide 7: 9M/Q3-FY19 Financial Highlights - Standalone
6 9M/ Q3-FY19 Financial Highlights - Standalone PARTICULARS (INR Mn) Q3-FY19 Q3-FY18 Y-O-Y Q2-FY19 Q-O-Q 9M-FY19 9M-FY18 Y-O-Y Turnover 1,499 1,188 26.2% 1,188 26.2% 3,766 2,768 36.0% Gross Margin 338 220 53.6% 323 4.6% 982 654 50.1% Gross Margin % 22.54% 18.52% 402 Bps 27.18% (464) Bps 26.08% 23.62
Slide 8: 9M/Q3-FY19 Financial Highlights - Consolidated
7 9M/ Q3-FY19 Financial Highlights - Consolidated PARTICULARS (INR Mn) Q3-FY19 Q3-FY18 Y-O-Y Q2-FY19 Q-O-Q 9M-FY19 9M-FY18 Y-O-Y Turnover 2,414 2,077 16.2% 2,013 19.9% 6,241 4,946 26.2% Gross Margin 1,143 859 33.1% 966 8.3% 3,044 2,035 49.6% Gross Margin % 47.34% 41.35% 599 Bps 47.98% (64) Bps 48.77
Slide 9: Country Overview
88 COUNTRY OVERVIEW
Slide 10: CFS India
99 CFS India • R&D Centre at Tarapur that has developed many new Diphenol-downstream products • Shelf Life Solutions Development, Testing and Applications Lab at Mumbai that works on testing food formulations and blends for the food, pet food and animal nutrition industries. • Provides technical exp
Slide 11: Update on Dahej Project
10 10 Update on Dahej Project Work / Activities completed • Financial Closing achieved • Basic Process & Mechanical Equipment Engineering • Long lead equipment (process & utility) as well as major equipments– Orders placed Time lines • Civil / Structural Engineering for major non-process buildings,
Slide 12: CFS Mexico
11 11 CFS Mexico • Acquire 65% stake in Dresen Quimica SAPI De CV, Mexico in May 2016 • Primarily manufactures Blends and Additives • Key customer segments: Oil, Poultry, Diary, Rendering, Aqua, Pet food, Swine, Vitamin Cuba Pre-mix Mexico city Republic of • Total Market size is ~USD 200 Mn and CFS
Slide 13: CFS Europe
12 12 CFS Europe Performance Chemicals • Acquired the manufacturing facility at Ravenna, Italy in 2011, which provides captive requirements of key raw materials i.e. Hydroquinone and Catechol • Capacity utilization achieved at 95% in 9M-FY19 • Considrable growth in EBITDA Margins & Profits due to co
Slide 14: CFS Brazil
13 13 CFS Brazil Shelf Life Solutions • Formed in 2013 for Blends and the production started in 2015 • Has an application lab in Indaiatuba – Brazil for customizing blends for Shelf-life Extension Solutions. • Handles distribution of bulk antioxidants and vanillin. Indaiatuba, Brazil • Key customer
Slide 15: CFS Wanglong
14 14 CFS Wanglong • CFS along with CFS Europe acquired 51% stake in Ningbo Wanglong Flavours in 2017 which had an operational plant since 2011. • This acquisition makes CFS the 3rd largest producer of Vanillin • Located in Grade 1 Industrial zone in the city of Yuyao Zhejiang Province, China. • It
Slide 16: CFS North America
15 15 CFS North America Shelf Life Solutions • Formed in October 2015 as a wholly owned subsidiary Market focus • Food - Bulk oils (synthetic antioxidants), Meat & poultry (natural antioxidants) Iowa, USA • Pet food - Rendering for pet food (natural antioxidants), Rendering for animal feed (syntheti
Slide 17: Historical Financial Overview
16 HISTORICAL FINANCIAL OVERVIEW
Slide 18: Standalone Income Statement
17 Standalone Income Statement PARTICULARS (INR Mn) FY16 FY17* FY18* Operational Income 4,227 3,376 4,050 Total Expenses 3,553 3,156 3,992 EBITDA 674 220 58 EBITDA Margin 15.94% 6.52% 1.43% Depreciation 101 116 91 Finance Cost 218 232 240 Other Income 37 129 92 Exceptional Items 45 - - PBT 347 1 (18
Slide 19: Standalone Balance Sheet (IND-AS)
18 Standalone Balance Sheet (IND-As) PARTICULARS (INR Mn) FY17 FY18 H1-FY19 PARTICULARS (INR Mn) FY17 FY18 H1-FY19 EQUITY 1,757 3,314 3,481 Non-Current Assets 1,592 1,596 2,145 a) Equity Share Capital 104 121 121 a) Property, Plant and Equipment 756 683 647 b) Other Equity 1,653 3,193 3,360 b) Capit
Slide 20: Consolidated Income Statement
19 Consolidated Income Statement PARTICULARS (INR Mn) FY16 FY17* FY18* Operational Income 5,042 5,469 7,228 Total Expenses 4,125 5,187 7,072 EBITDA 917 282 156 EBITDA Margin 18.19% 5.16% 2.16% Depreciation 171 218 267 Finance Cost 244 269 284 Other Income 43 145 86 Exceptional Items (45) - - Income
Slide 21: Consolidated Balance Sheet (IND-AS)
20 Consolidated Balance Sheet (IND-As) PARTICULARS (INR Mn) FY17 FY18 H1-FY19 PARTICULARS (INR Mn) FY17 FY18 H1-FY19 EQUITY 2,302 4,334 4,392 Non-Current Assets 2,531 3,510 3,647 a) Equity Share Capital 104 121 121 a) Property, Plant and Equipment 1,525 2,066 2,017 b) Other Equity 2,022 3,591 3,570
Slide 22: Consolidated Financial Highlights
21 Consolidated Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margin (%) 8,000 7,228 1,200 18.19% 20.00% 6,000 5,469 900 15.00% 5,042 917 4,000 600 10.00% 5.16% 2,000 300 2.16% 5.00% 282 156 - - 0.00% FY16* FY17 FY18 FY16* FY17 FY18 Net Debt to Equity Net Worth (INR Mn)
Slide 23: Capital Markets
22 Capital Markets 22 Share Price Data as on 31st December, 2018 20% 0% -20% -40% -60% -80% Jan-18 Feb-18 Mar-18 Apr-18 May-18 Jun-18 Jul-18 Aug-18 Sep-18 Oct-18 Nov-18 Dec-18 Camlin Sensex Price Data (31st December, 2018) INR Shareholding Pattern as on 31st December, Face Value 1.00 2019 Market Pri
Slide 24: Disclaimer
23 Disclaimer 23 Camlin Fine Sciences Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in
Slide 25: Thank You
24 Thank You